MAP2K7 and melanoma: A total of 97 patients (40 females and 57 males, overall median age 55 years) with advanced melanoma treated with BRAF inhibitors in monotherapy (41.2%) or in combination with MEK inhibitors (58.8%) were included in the analysis.